These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8352267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
    Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E.
    J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
    [Abstract] [Full Text] [Related]

  • 3. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
    Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA.
    Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
    Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B.
    Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
    [Abstract] [Full Text] [Related]

  • 10. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA.
    N Engl J Med; 1998 Aug 27; 339(9):578-83. PubMed ID: 9718376
    [Abstract] [Full Text] [Related]

  • 11. The effect of epoetin dose on hematocrit.
    Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA.
    Kidney Int; 2008 Feb 27; 73(3):347-53. PubMed ID: 18004296
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A, Puggia RM, Fusaro M, Favaro E, Pillon L.
    Pharmacoeconomics; 1995 May 27; 7(5):444-56. PubMed ID: 10155331
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous.
    Hörl WH.
    Acta Haematol; 1992 May 27; 87 Suppl 1():16-9. PubMed ID: 1574961
    [Abstract] [Full Text] [Related]

  • 19. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure.
    Zappacosta AR, Perras ST, Bell A.
    Am J Med; 1991 Sep 27; 91(3):229-32. PubMed ID: 1892142
    [Abstract] [Full Text] [Related]

  • 20. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
    Saleh A, Krane NK, Caballero M, Starks E.
    Adv Perit Dial; 1991 Sep 27; 7():288-91. PubMed ID: 1680448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.